Galectin Therapeutics Inc (GALT)
2.78
+0.06
(+2.21%)
USD |
NASDAQ |
Nov 22, 16:00
2.77
-0.01
(-0.36%)
After-Hours: 20:00
Galectin Therapeutics Enterprise Value: 254.19M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 254.19M |
| November 21, 2024 | 250.43M |
| November 20, 2024 | 256.39M |
| November 19, 2024 | 252.63M |
| November 18, 2024 | 248.55M |
| November 15, 2024 | 253.57M |
| November 14, 2024 | 252.31M |
| November 13, 2024 | 261.73M |
| November 12, 2024 | 265.49M |
| November 11, 2024 | 261.10M |
| November 08, 2024 | 268.00M |
| November 07, 2024 | 256.67M |
| November 06, 2024 | 254.80M |
| November 05, 2024 | 242.03M |
| November 04, 2024 | 237.04M |
| November 01, 2024 | 235.49M |
| October 31, 2024 | 233.62M |
| October 30, 2024 | 236.73M |
| October 29, 2024 | 238.29M |
| October 28, 2024 | 234.86M |
| October 25, 2024 | 236.11M |
| October 24, 2024 | 238.60M |
| October 23, 2024 | 240.47M |
| October 22, 2024 | 242.96M |
| October 21, 2024 | 243.59M |
| Date | Value |
|---|---|
| October 18, 2024 | 246.08M |
| October 17, 2024 | 245.46M |
| October 16, 2024 | 243.59M |
| October 15, 2024 | 241.72M |
| October 14, 2024 | 243.59M |
| October 11, 2024 | 247.95M |
| October 10, 2024 | 240.47M |
| October 09, 2024 | 243.59M |
| October 08, 2024 | 250.44M |
| October 07, 2024 | 245.46M |
| October 04, 2024 | 255.43M |
| October 03, 2024 | 249.20M |
| October 02, 2024 | 249.20M |
| October 01, 2024 | 249.20M |
| September 30, 2024 | 251.06M |
| September 27, 2024 | 238.82M |
| September 26, 2024 | 235.08M |
| September 25, 2024 | 233.84M |
| September 24, 2024 | 236.33M |
| September 23, 2024 | 239.44M |
| September 20, 2024 | 242.56M |
| September 19, 2024 | 246.92M |
| September 18, 2024 | 238.82M |
| September 17, 2024 | 242.56M |
| September 16, 2024 | 239.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
40.90M
Minimum
Mar 18 2020
322.15M
Maximum
Apr 11 2024
143.56M
Average
128.04M
Median
Aug 01 2023
Enterprise Value Benchmarks
| Microbot Medical Inc | 12.26M |
| Alaunos Therapeutics Inc | 2.144M |
| SELLAS Life Sciences Group Inc | 61.32M |
| Oragenics Inc | 2.314M |
| Anavex Life Sciences Corp | 633.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.22M |
| Total Expenses (Quarterly) | 9.066M |
| EPS Diluted (Quarterly) | -0.18 |
| Earnings Yield | -26.26% |